PMC in 2017

President's Letter

Dear Colleague:

According to Michael Pellini, CEO of Foundation Medicine and PMC board member, "We have to think about this space differently because ‘standard of care’ is not good enough.”

His comment, which came in a panel discussion at the Personalized Medicine Coalition’s 12th Annual Personalized Medicine Conference at Harvard Medical School in November of 2016, sums up PMC’s central premise: to improve patient care and also make the health care system more efficient, we have to continue to develop and integrate innovative diagnostic technologies into medicine. And to do that, we have to be willing to examine old ways of doing things and, when appropriate, replace them with new approaches.

Patients deserve no less, and while many organizations advocate for personalized or precision medicine, PMC is the only group that convenes all the field’s stakeholders to make the case for its development and adoption. Focused on only one issue, PMC organizes many perspectives into one vision.

That vision has never been more compelling. As documented by PMC's Progress Report, the Coalition’s educational and advocacy efforts had a real impact on the field in 2016 during a remarkable year of advances that have ranged from the development of the Precision Medicine Initiative to the pharmaceutical industry’s increasing investment in developing targeted therapeutics, now numbering 131, up from only five in 2008.

Our work, however, is hardly done, and it will undoubtedly become more difficult in 2017 when a new administration reviews its health care priorities with little knowledge of the power and purpose of personalized medicine.

As our Strategic Plan for 2017 shows, we have in place a comprehensive educational and advocacy effort to help improve the landscape for investment in and delivery of personalized medicine, not only in the United States but also across the globe. The plan includes the publication of a new Personalized Medicine Report, which will serve as the primer that defines the field, as well as advocacy for multiple public policy projects. These projects will advance our goal of moving away from one-size-fits-all/trial-and-error medicine.

None of this will be possible, though, without your support.

On behalf of all of our members, I would like to extend my thanks in advance for your commitment.

Sincerely yours,

Edward Abrahams
Personalized Medicine Coalition